Comments on: Another Biotech Windfall from the SIFT Tax: Vasogen Molts for Cervus and Merges with IntelliPharmaCeutics. Shareholders Applaud.

By: First Reactions to Canada’s 2010 Federal Budget From Biotech, Venture Capital and Innovation Groups « The Cross-Border Biotech Blog

Thu, 04 Mar 2010 21:39:31 +0000

[...] Is this the end of the SIFT/SR&ED deals? Looks that way: “Ensure that income trust conversions into corporations are subject to the [...]

By: Monday Biotech Deal Review: January 25, 2010 « The Cross-Border Biotech Blog

Mon, 25 Jan 2010 12:03:09 +0000

[...] share price unmoved and didn’t drive unusual volume. Maybe now that ConjuChem, Vasogen and SemBioSys paved the way, the market is truly viewing these as [...]

By: Monday Biotech Deal Review: November 2, 2009 « The Cross-Border Biotech Blog

Tue, 03 Nov 2009 08:06:51 +0000

[...] Genetics Inc. (TSX: SBS) has signed up a SIFT tax plan of arrangement with Cathedral Energy, along the lines of earlier deals by ConjuChem (with Colabor) and Vasogen (with Cervus and IntelliPharmaCeutics). SemBioSys [...]

By: Monday Biotech Deal Review: October 25, 2009 « The Cross-Border Biotech Blog

Mon, 26 Oct 2009 16:33:08 +0000

[...] impressed with the IntelliPharmaCeutics-Vasogen-Cervus deal when it was announced in August, and so were shareholders. Following their approval of the plan of arrangement and merger, the [...]

By: Monday Deal Review: August 24, 2009 « The Cross-Border Biotech Blog

Monday Deal Review: August 24, 2009 « The Cross-Border Biotech Blog — Mon, 24 Aug 2009 11:02:34 +0000

[...] · Leave a Comment This week saw a few headline deals that we covered at the time, including the Vasogen-Cervus-IntelliPharmaCeutics deal, the move by Takeda Canada to take back ACTOS rights from Lilly, and the Lonza offer for [...]